Hoth Partners with the Department of Veterans Affairs to Develop Obesity Treatment

 Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University

Hoth Also Expands Its' Intellectual Property to Further Its' Market Opportunity for HT-001

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative therapies, today announced that it has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA). This agreement provides Hoth with exclusive rights to a jointly owned patent portfolio co-developed by the VA and Emory University.

The licensed technology centers on "Glial Cell Line-Derived Neurotrophic Factor, Obesity, and Obesity-Related Diseases and Conditions," a groundbreaking innovation aimed at addressing critical challenges in treating obesity and associated health conditions. This agreement underscores Hoth Therapeutics' commitment to advancing transformative healthcare solutions.

Under the terms of the agreement, Hoth Therapeutics will have exclusive rights to develop, market, and commercialize products and processes derived from the licensed patents. The VA and Emory University have granted Hoth this license to further develop the technology with the goal of ensuring the benefits of this innovation are accessible to the widest audience possible.

https://www.prnewswire.com/news-releases/hoth-therapeutics-enters-partnership-with-the-department-of-veterans-affairs-to-develop-obesity-treatment-302339151.html